Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

BOULDER, Colo. and MONTREAL, Jan. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the enrollment of the first patient in a Phase 2 clinical trial (Trial CL002) evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Vidaza(R) (azacitidine for injection), Pharmion's DNA demethylating agent, in patients with relapsed or refractory Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL).

Patients will receive 75 mg/m2 of Vidaza either intravenously or subcutaneously in combination with an oral dose of MGCD0103 in 28 day cycles. Key objectives for this study are to determine the overall response rate, progression free survival and duration of response. The trial will enroll up to 75 patients at cancer centers in North America and will include a pharmacokinetic equivalency study.

"We are aggressively exploring the utility of epigenetic drug combinations in the treatment of cancer," said Andrew Allen, Pharmion's executive vice president and chief medical officer. "The biology of cancer suggests multiple epigenetic mechanisms cooperate to silence tumor suppressor genes, which raises the simple hypothesis that attacking these mechanisms with drug combinations may be superior to single-agent therapy. In this trial, we are combining Vidaza, our DNA methyltransferase inhibitor, with MGCD0103, our isotype-selective HDAC inhibitor, in a clinical study of this therapeutic approach. We are unique in our ability to conduct a trial like this, using drugs from our own portfolio."

"We are delighted to be participating in this trial of Vidaza and MGCD0103," commented Dr. Anas Younes, Professor of Medicine
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015 Konica Minolta ... Computed Radiography (CR) system, designed to deliver enterprise level ... utilizing the same Control Station as the Konica Minolta ... with an upgrade path from CR to DR. The ... to help improve workflow with unparalleled reliability and high ...
(Date:9/1/2015)... VEGAS , Sept. 1, 2015  Dr. ... DigiPath Labs , the cannabis testing subsidiary of DigiPath, ... Patients Group about the lack of consistency in ... the online resource for medical cannabis information, she explained ... patients because their lack of uniform requirements makes standardization ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
... California, June 6 , - "ADVANCE Results ... the world,s largest ever study of diabetes treatments,show ... release,gliclazide and other drugs as required, protects patients ... treatment reduces,the risk of kidney disease by one-fifth. ...
Cached Medicine Technology:New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor ... , Based in San Francisco, Doctor On Demand provides immediate access to Board ...
(Date:9/1/2015)... ... 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and founder ... firm’s success in the hair care and distribution industry through her combination of ... be providing “Look and learn” live demonstrations, as well as promoting her new ...
(Date:9/1/2015)... Melbourne, Florida (PRWEB) , ... ... ... Association of Professional Background Screeners (NAPBS®) has announced that Edge Information ... audit conducted by the Background Screening Credentialing Council (BSCC). , “Achieving ...
(Date:9/1/2015)... Winston-Salem, NC (PRWEB) , ... September 01, 2015 , ... ... (Science, Technology, Engineering and Math) disciplines since its inception more than 35 years ago. ... and high-school students and their teachers - and, not just those intent on pursuing ...
(Date:9/1/2015)... ... 2015 , ... Royal River Natural Foods, a locally-owned independent natural health store ... 19 years and found that, among those who had a stroke, people who used ... part of the September 2015 issue of “Natural Insights for Well Being,” which Royal ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... ... ... Noni International (TNI) announced the introduction of two new bioactive beverages in grape and ... loaded with iridoids and other bioactive compounds that support the immune system, neutralize ...
... ... Children,s Advancement Society , ... Sydney, New South Wales (PRWEB) November 29, 2009 -- Australia Souvenir Gift Shop ... Australian souvenirs online to the ACAS (Aboriginal Children,s Advancement Society), a New South Wales ...
... ... reports of severe tissue and bone damage , ... (PRWEB) March 17, 2010 -- According to a recent story in the New York ... of metal on metal artificial hips. New York personal injury attorney David Perecman comments ...
... ... powerful effect. Now it,s proven by Dr. Emoto. In Japan, Dr. Masaru Emoto photographed water ... Emoto could see that the water was miraculously changed to a beautiful snowflake effect. , ... Los Angeles, CA (PRWEB) March 17, 2010 -- ...
... ) announced today that Robert Myers , the company,s President, will present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 at ... ... ... ...
... , WASHINGTON , March 16 A ... human origins opens March 17 at the Smithsonian,s ... research by Smithsonian scientists, the David H. Koch (pronounced "coke") ... a special preview from noon to 3 p.m. Wednesday, ...
Cached Medicine News:Health News:Tahitian Noni Family Released in Grape and Mango Passionfruit 2Health News:Australia Souvenir Gift Shop Donates 10% Of Profits To Help Aboriginal Children 2Health News:Australia Souvenir Gift Shop Donates 10% Of Profits To Help Aboriginal Children 3Health News:New York Personal Injury Attorney David Perecman Comments On Dangers Of ‘Metal On Metal' Hip Implants 2Health News:The Power of James Bond Symbols Proven by Dr. Emoto 2Health News:The Power of James Bond Symbols Proven by Dr. Emoto 3Health News:Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 2Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 3Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 4Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 5Health News:New Exhibition Hall Devoted to Human Origins Opens at National Museum of Natural History 6
... clinical and economic issues of cerclage wiring, ... to maximize tension control while minimizing invasion ... efficient instrumentation with a simple technique. , ... indicated for general orthopaedic trauma surgery involving: ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... aggressive innovations have become the accepted standard ... The AML Total Hip System was ... and effectively meet the needs for biological ... greater than 15 years of documented clinical ...
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Medicine Products: